Table 1.
Characteristics of patients from the TUH cohort.
| 2087 patients | TUH cohort | HSC-L | MPP-L | CMP-L | GMP-L | GP-L | MP-L |
|---|---|---|---|---|---|---|---|
| Patients | |||||||
| Age (median and IQR, years) | 65 (54–75) | 61 (40–78) | 69 (60–78) | 69 (58–77) | 62 (44–73) | 69 (58–75) | 63 (51–72) |
| <60 yr (%) | 692 (33.2) | 7 (38.9) | 112 (24.5) | 174 (27.6) | 162 (45.0) | 34 (28.6) | 203 (40.4) |
| ≥60 yr (%) | 1395 (66.8) | 11 (61.1) | 346 (75.5) | 456 (72.4) | 198 (55.0) | 85 (71.4) | 299 (59.6) |
| AML status | |||||||
| De novo | 1423 (70.2) | 13 (72.2) | 243 (53.1) | 400 (63.5) | 276 (76.7) | 96 (80.7) | 395 (78.7) |
| Secondary to MDS | 247 (12.2) | 4 (22.2) | 75 (16.4) | 103 (16.3) | 24 (6.7) | 5 (4.2) | 36 (7.2) |
| Secondary to MPN | 142 (7.0) | 1 (5.6) | 70 (15.3) | 51 (8.1) | 12 (3.3) | 3 (2.5) | 5 (1.0) |
| Therapy-related | 245 (12.1) | 0 (0.0) | 62 (13.5) | 73 (11.6) | 43 (11.9) | 12 (10.1) | 55 (11.0) |
| Unknown | 30 (1.5) | 0 (0.0) | 8 (1.7) | 3 (0.5) | 5 (1.4) | 3 (2.5) | 11 (2.2) |
| Extramedullary disease | |||||||
| Liver | 100/1603 | 4/10 | 22/326 | 18/484 | 19/295 | 5/93 | 32/395 |
| Spleen | 161/1603 | 3/10 | 45/326 | 44/484 | 23/295 | 6/93 | 40/395 |
| Lymph nodes | 174/1603 | 4/10 | 26/326 | 37/484 | 32/295 | 10/93 | 65/395 |
| Gingiva | 148/1603 | 0/10 | 11/326 | 30/484 | 23/295 | 10/93 | 74/395 |
| Skin | 56/1603 | 3/10 | 3/326 | 14/484 | 10/295 | 1/93 | 25/395 |
| Complete Blood Count (median and IQR) | |||||||
| Hemoglobin (g/L) | 9.3 (8.2–10.7) | 8.9 (8.3–11.1) | 9.0 (8.0–10.2) | 9.3 (8.2–10.8) | 9.4 (8.3–10.9) | 9.4 (8.2–11.1) | 9.6 (8.3–10.9) |
| Platelet count (g/L) | 62 (33–112) | 75 (37–163) | 62 (29–120) | 64 (31–115) | 56 (32–101) | 62 (34–98) | 63 (39–110) |
| WBC count (g/L) | 8.01 (2.40–36.79) | 3.90 (1.40–12.76) | 5.08 (2.05–20.20) | 3.60 (1.80–15.53) | 8.68 (2.88–44.98) | 15.34 (6.9–80.10) | 24.72 (4.30–71.36) |
| Bone marrow evaluation | |||||||
| Blasts (median and IQR, %) | 52 (30–77) | 63 (39–90) | 44 (29–69) | 36 (24–61) | 59 (37–76) | 86 (62–93) | 69 (44–86) |
| Cytological dysmyelopoiesis | 912/1898 | 5/16 | 219/401 | 369/583 | 131/337 | 23/99 | 165/462 |
| Cytogenetic risk | |||||||
| Favorable (%) | 139 (6.9) | 0 (0.0) | 0 (0.0) | 15 (2.4) | 119 (33.7) | 1 (0.9) | 4 (0.8) |
| Intermediate (%) | 1258 (62.0) | 9 (50.0) | 221 (50.7) | 343 (55.7) | 165 (46.7) | 103 (91.1) | 417 (84.8) |
| Adverse (%) | 631 (31.1) | 9 (50.0) | 215 (49.3) | 258 (41.9) | 69 (19.5) | 9 (8.0) | 71 (14.4) |
| Mutation status (mutated/tested) | |||||||
| CEBPA mono or bi-allelic | 69/865 | 0/6 | 1/163 | 9/248 | 41/125 | 4/59 | 14/264 |
| DNMT3A (exon 23) | 130/884 | 0/8 | 13/163 | 32/250 | 8/155 | 6/58 | 71/250 |
| FLT3-ITD | 295/1456 | 5/13 | 40/264 | 61/399 | 28/258 | 35/94 | 126/428 |
| FLT3-TKD | 57/818 | 1/6 | 8/159 | 15/234 | 8/152 | 4/55 | 21/212 |
| IDH1 | 101/1120 | 0/8 | 10/231 | 29/325 | 12/193 | 13/72 | 37/291 |
| IDH2 | 134/1120 | 1/8 | 25/231 | 45/325 | 23/193 | 17/72 | 23/291 |
| NPM1 | 427/1421 | 0/9 | 16/271 | 49/394 | 18/232 | 75/94 | 269/421 |
| Treatment | |||||||
| Intensive chemotherapy (%) | 1266 (60.7) | 12 (66.7) | 192 (41.9) | 325 (51.6) | 269 (74.7) | 88 (73.9) | 380 (75.7) |
| Allo-SCT (%) | 299 (14.3) | 3 (16.7) | 69 (15.1) | 88 (14.0) | 50 (13.9) | 11 (9.2) | 78 (15.5) |
| Hypomethylating agents (%) | 340 (16.3) | 1 (5.6) | 109 (23.8) | 149 (23.7) | 40 (11.1) | 4 (3.4) | 37 (7.4) |
| Best supportive care (%) | 298 (14.3) | 2 (11.1) | 102 (22.3) | 96 (15.2) | 30 (8.3) | 12 (10.1) | 56 (11.2) |
| Other (%) | 183 (8.7) | 3 (16.7) | 55 (12.0) | 60 (9.5) | 21 (5.8) | 15 (12.6) | 29 (5.8) |